卡瑞利珠单抗相关不良反应分析

Analysis of adverse drug reactions related to carilizumab

目的分析卡瑞利珠单抗相关不良反应报告,探讨其发生规律及临床特点,以期为临床安全合理用药提供参考。方法收集2021年7月至2023年1月期间临沂市中心医院上报的卡瑞利珠单抗相关不良反应报告,分析患者的基本情况、不良反应发生时间、临床表现、预后及转归等。结果研究共纳入卡瑞利珠单抗相关不良反应报告21例,其中严重不良反应13例(61.9%);涉及18例患者,其中,男性11例(61.1%),女性7例(38.9%),主要分布在55岁以上年龄段(77.8%);不良反应以血液毒性占比最高,其次为皮肤黏膜毒性和内分泌毒性。结论临床应关注卡瑞利珠单抗相关不良反应,准确识别,及早干预,保证安全用药。

Objective To analyze the ADRs related to carilizumab,and to explore its occurrence patterns and clinical characteristics,so as to provide references for clinical safe and rational drug use.Methods We collected ADR reports re⁃lated to carilizumab from Linyi Central Hospital between July 2021 and January2023.Patient demographics,time of ADRs occurrence,clinical manifestations and outcomes were analyzed.Results A total of 21 ADR reports were included,of which 13 patients(61.9%)were severe.These reports involved 18 patients,with 11 males(61.1%)and 7 females(38.9%).The majority of these patients were over 55 years old(77.8%).Hematological toxicity was the most prevalent adverse reaction,followed by dermatologic and mucosal toxicity,and endocrine toxicity.Conclusion Clinicians should pay attention to ADRs related to carilizumab,identify them accurately,intervene early to ensure the safe administration of the drug.